Vinorelbine

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4548 publications

Cytostatic and Non-Apoptotic Effects of Vinorelbine-Based Therapy in 3D Endometrial Cancer Spheroids.

Cytostatic and Non-Apoptotic Effects of Vinorelbine-Based Therapy in 3D Endometrial Cancer Spheroids.

Journal: Biology
Published: March 10, 2026

Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term study. Blood. 2025;146(suppl 1):1847.

Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term study. Blood. 2025;146(suppl 1):1847.

Journal: Blood
Published: February 05, 2026

Antineoplastic drug contamination and safe handling practices in Canadian healthcare centres: Results from the 2025 monitoring program.

Antineoplastic drug contamination and safe handling practices in Canadian healthcare centres: Results from the 2025 monitoring program.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: January 27, 2026

Safety analysis of vinorelbine in the real world: a pharmacovigilance study based on the FAERS database.

Safety analysis of vinorelbine in the real world: a pharmacovigilance study based on the FAERS database.

Journal: Journal of chemotherapy (Florence, Italy)
Published: January 23, 2026

Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss.

Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss.

Journal: Cancers
Published: January 14, 2026

Update on pediatric soft tissue sarcomas.

Update on pediatric soft tissue sarcomas.

Journal: Current opinion in pediatrics
Published: December 26, 2025

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis.

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis.

Journal: Cancers
Published: December 22, 2025

Identification of an m7G-Related lncRNA Signature for Prognostic Prediction and Immune Landscape Characterization in Early Gastric Cancer.

Identification of an m7G-Related lncRNA Signature for Prognostic Prediction and Immune Landscape Characterization in Early Gastric Cancer.

Journal: OncoTargets and therapy
Published: December 15, 2025

Proteasome Inhibitor-Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines.

Proteasome Inhibitor-Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines.

Journal: Veterinary and comparative oncology
Published: December 12, 2025

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 02, 2025

Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.

Locoregional recurrence of triple-negative breast cancer with low tumor-infiltrating lymphocytes: a case report.

Journal: The Pan African medical journal
Published: December 01, 2025

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme.

Journal: Research square
Published: November 24, 2025
Showing 1-12 of 4,548

Last Updated: 04/28/2026